Press release
Investigation was announced for Investors in shares of BeiGene, Ltd. (NASDAQ: BGNE)
An investigation for investors in BeiGene, Ltd. (NASDAQ: BGNE) shares over potential securities laws violations by BeiGene, Ltd.
Investors who purchased shares of BeiGene, Ltd. (NASDAQ: BGNE), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by BeiGene, Ltd. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
China based BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer in the People's Republic of China, the United States, and internationaly.
On September 5, 2019, a report was published concerning BeiGene, Ltd. The report asserted, inter alia, that BeiGene “is faking sales in order to persuade investors that it can develop a successful platform in China” and that “management may also be skimming R&D and capital budgets.”
Shares of BeiGene, Ltd. (NASDAQ: BGNE) declined to as low as $118.00 per share on September 6, 2019.
Those who purchased shares of BeiGene, Ltd. (NASDAQ: BGNE) have certain options and should contact the Shareholders Foundation.
Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation was announced for Investors in shares of BeiGene, Ltd. (NASDAQ: BGNE) here
News-ID: 1833537 • Views: …
More Releases from Shareholders Foundation
Lawsuit Alert: Investors who lost money with James Hardie Industries plc (NYSE: …
An investor, who purchased shares of James Hardie Industries plc (NYSE: JHX), filed a lawsuit over alleged violations of Federal Securities Laws by James Hardie Industries plc in connection with certain allegedly false and misleading statements.
Investors who purchased shares of James Hardie Industries plc (NYSE: JHX) have certain options and for certain investors are short and strict deadlines running. Deadline: December 23, 2025. NYSE: JHX investors should contact the Shareholders…
Investigation announced for Long-Term Investors in SelectQuote, Inc. (NYSE: SLQT …
An investigation on behalf of current long-term investors in shares of SelectQuote, Inc. (NYSE: SLQT) concerning potential breaches of fiduciary duties by certain directors and officers of SelectQuote, Inc. was announced.
Investors who are current long term investors in SelectQuote, Inc. (NYSE: SLQT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term…
Lawsuit filed for Investors who lost money with shares of MoonLake Immunotherape …
An investor, who purchased shares of MoonLake Immunotherapeutics (NASDAQ: MLTX), filed a lawsuit over alleged violations of Federal Securities Laws by MoonLake Immunotherapeutics in connection with certain allegedly false and misleading statements.
Investors who purchased a significant amount of shares of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, have certain options and for certain investors are short and strict deadlines running. Deadline: December 15, 2025. NASDAQ:…
Dow Inc. (NYSE: DOW) Investor Alert: Deadline in Lawsuit on October 28, 2025
A deadline is coming up on October 28, 2025 in the lawsuit filed for certain investors of Dow Inc. (NYSE: DOW) over alleged securities laws violations by Dow Inc.
Investors who purchased shares of Dow Inc. (NYSE: DOW) have certain options and there are strict and short deadlines running. Deadline: October 28, 2025. Dow Inc. (NYSE: DOW) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -…
More Releases for BeiGene
Waldenstrom Macroglobulinemia Market Growth, Trends & Forecast 2024-2031 | Top k …
The latest report published by DataM Intelligence highlights the growth prospects of Waldenstrom Macroglobulinemia market. The industry expansion is majorly driven by developments in technology across the globe.
Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/waldenstrom-macroglobulinemia-market?sz
The Global Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Market is estimated to reach at a Significant CAGR during the forecast period 2024-2031.
Waldenstrom Macroglobulinemia (WM) is a rare type of cancer…
Advanced Gastric Carcinoma Pipeline 2024 | Jiangsu Hengrui Medicine, BeiGene, CS …
DelveInsight's, "Advanced Gastric Carcinoma Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Advanced Gastric Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Advanced Gastric Carcinoma Research.…
Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Market 2024 Size, Glo …
A new Report by DataM Intelligence, titled "Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2031,"" offers a comprehensive analysis of the industry, which comprises insights on the Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) market analysis. The report also includes competitor and regional analysis, and contemporary advancements in the market.
This report has a complete table of contents, figures, tables, and charts, as well as insightful analysis. The…
Bruton’s Tyrosine Kinase (BTK) Inhibitor Market | AbbVie, ArQule, BeiGene …
The global bruton’s tyrosine kinase (btk) inhibitor market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the bruton’s tyrosine kinase (btk) inhibitor market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants.
From the perspective of market dynamics, this report explores the…
Bruton's Tyrosine Kinase (BTK) Inhibitors Market Business Standards - BeiGene, L …
MarketQuest.biz proclaims the addition of another new report titled Global Bruton's Tyrosine Kinase (BTK) Inhibitors Market which is a well-synchronized synopsis of the market. The report offers broad insights extracted by thoroughly analyzing historical and current developments in the market. The report outlines the distinguishable players in the global Bruton's Tyrosine Kinase (BTK) Inhibitors market with a clear-cut end goal to give an intelligent standpoint of the forces of the…
Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size [2023-2031] - …
Newark, New Castle, USA - The latest report from Growth Plus Reports analyzes the production, potential applications, demand, major manufacturers, and SWOT analysis of the global Gastroesophageal Junction Adenocarcinoma Therapeutics Market.
The Gastroesophageal Junction Adenocarcinoma Therapeutics Market Report assists in determining the optimum distribution methods for certain products as well as possible markets for future product launches. The report also analyses the purchase and supply trends that influence the market's production…
